Will U.K.'s Big 3 Health-Care Stocks Bounce Back in 2016?: Chart
This article is for subscribers only.
During a record year of consolidation and markets rocked by drug-pricing controversies, the U.K.’s big three health-care companies embarked on deals in inverse proportion to their size: GlaxoSmithKline Plc announced about $650 million in transactions while AstraZeneca Plc’s total approached $7.8 billion and Shire Plc about $47 billion. All three ended the year with similar returns:
Here’s what lies ahead in 2016 for each company: